Performance of the ESC/ERS 4-strata risk stratification model for pulmonary arterial hypertension with missing variables

Christine Pausch; David Pittrow; Marius M Hoeper; Doerte Huscher

doi:10.1183/13993003.01023-2023

Performance of the ESC/ERS 4-strata risk stratification model for pulmonary arterial hypertension with missing variables

Eur Respir J. 2023 Nov 29;62(5):2301023. doi: 10.1183/13993003.01023-2023. Print 2023 Nov.

Authors

Christine Pausch¹, David Pittrow^{1

2}, Marius M Hoeper^{3

4}, Doerte Huscher⁵

Affiliations

¹ GWT-TUD GmbH, Innovation Center Real-World Evidence, Dresden, Germany.
² Institute for Clinical Pharmacology, Medical Faculty, Technical University, Dresden, Germany.
³ Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany [email protected].
⁴ German Center for Lung Research (DZL), Biomedical Research in Endstage and Obstructive Lung Disease Hanover (BREATH), Hannover, Germany.
⁵ Institute of Biometry and Clinical Epidemiology, and Berlin Institute of Health, Charité-Universitätsmedizin, Berlin, Germany.

Abstract

In patients with PAH, the ESC/ERS 4-strata risk model maintains some of its discriminative power when one of the three parameters (WHO-FC, 6MWD, and BNP/NT-proBNP) is missing, although with an increasing likelihood of overestimating risk https://bit.ly/46mz83d

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Familial Primary Pulmonary Hypertension
Humans
Hypertension, Pulmonary*
Pulmonary Arterial Hypertension*
Risk Assessment